Zhengbin Yao - 02 Feb 2026 Form 4 Insider Report for ArriVent BioPharma, Inc. (AVBP)

Reporting relationship: President and CEO, Director
Issuer ticker: AVBP
Reported as of: 02 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Feb 2026, 20:40:04 UTC
Prior SEC filing: 01 Aug 2025
Next SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ James Kastenmayer, Attorney-in-Fact for Zhengbin Yao

Key filing fact

Zhengbin Yao filed Form 4 for ArriVent BioPharma, Inc. (AVBP) on 04 Feb 2026.

Key facts

This page summarizes Zhengbin Yao's Form 4 filing for ArriVent BioPharma, Inc. (AVBP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Feb 2026, 20:40.

Change

Previous filing in this sequence was filed on 01 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001326228 Primary reporting owner

Yao Zhengbin

Relationship: President and CEO, Director
Address: C/O ARRIVENT BIOPHARMA, INC., 18 CAMPUS BOULEVARD, SUITE 100, NEWTOWN SQUARE
Signature: /s/ James Kastenmayer, Attorney-in-Fact for Zhengbin Yao
Signature date: 04 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVBP transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +550,000
Change %
Price: $0.000000
Shares after: 550,000
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 550,000
Exercise price: $22.67
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.